<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Target to Lead Selection for ADCs and Biologics

Journey through the drug discovery pipeline from target discovery to in vivo pharmacology. Take advantage of the Largest biobank of patient-derived models, Model development capabilities, Cell-based assays for Screening ADCs, and advanced downstream analysis.

Learn More

Immuno-oncology Targets & Combinations

Leverage comprehensive in vitro, in vivo, ex vivo, and in silico platforms, utilizing immunocompetent, humanized, or patient-derived models. With robust biomarker analysis and a focus on checkpoint inhibitors, you can optimize combination strategies.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Preclinical Consulting Services

Learn more about how our consulting services can help to support your journey to the clinic.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

On Demand Webinar

Targeting T Cells Within the Cancer Immunity Cycle

Speakers: Marrit Putker, PhD, Pirouz Daftarian, PhD, and Saskia De Man, PhD

Recent advances in cancer immunotherapy research have paved the way for the development of new clinical treatment options.

The cancer immunity cycle involves several sequential steps leading to an effective T cell-mediated tumor eradication. However, many steps in the cycle can be disrupted, resulting in a tumor evading the host’s immune surveillance and response.

Understanding the cancer immunity cycle as a whole and mechanisms at each step is important for developing immunotherapeutics with a more durable response.

One area of particular interest is the mechanisms and targets capable of modulating and enhancing T cell activity.

In this webinar Dr. Marrit Putker, Dr. Pirouz Daftarian and Dr. Saskia De Man focus on the impact of T cell-directed immunotherapy on the cancer-immunity cycle.

Mechanisms and targets capable of modulating and enhancing T cell activity are presented, including the application of relevant methods such as organoid models and co-cultures, and the integration of High Content Imaging (HCI).

Watch this educational and webinar to learn about:

  • Approaches to identify the right assays targeting T cell biology with immunotherapeutics at the different steps of the cancer immunity cycle such as T cell activation, migration, infiltration, and tumor killing.

  • Application of a unique 3D organoid platform with immune cell co-culture for immunotherapy studies and the advantages of autologous systems.

  • Integration of high content imaging-based screening to evaluate drug responses in 3D assays

  • Modeling T cell exhaustion in a more physiologically relevant in
    vitro human system

About The Presenters:


Saskia De Man, PhD, Scientist, Crown Bioscience

Dr. Saskia De Man performed her PhD research at the University of Amsterdam with Renée van Amerongen. Here, she used advanced imaging and gene editing techniques to study WNT/beta-catenin signalling at endogenous levels. During this time, she was also a Fulbright Scholar and joined the lab of Andres Lebensohn at the National Institutes of health for several months. Since finishing her PhD, Saskia has joined the immuno-oncology department at Crown Bioscience the Netherlands, where she applies her knowledge in cell biology and advanced microscopy to help clients test their immune modulatory drugs in a relevant 3D in vitro culture system.


Marrit Putker, PhD, Director, In Vitro and R&D, Crown Bioscience

Dr. Marrit Putker (Director in vitro & R&D) received training in molecular cancer biology at Utrecht University, followed by postdoctoral studies at the MRC LMB (Cambridge, UK) and the Hubrecht Institute (Utrecht, NL). Concentrating on tumor stem cell biology and drug sensitivity, she has developed and gained expertise in state-of-the-art organoid technologies while working in the lab of Prof. Dr. Clevers. In 2020, she joined Crown Bioscience to setup and lead the novel research site in Utrecht. From this organoid-research-dedicated laboratory, she now continues to manage Crown’s in vitro R&D activities, driving collaborations with academic and industry partners around the globe. 


Pirouz Daftarian, PhD, Director, Scientific Engagement, Crown Bioscience

Dr. Pirouz Daftarian completed his PhD training in immunology in Faculty of Medicine of the University of Ottawa, in 1998. Since then, he has been leading studies on cancer immunology and autoimmunity, in academia, and biotech. He joined Crown Bioscience / JSR Life Sciences in 2017 and led the developing applications for IO products and as a Director of Scientific Engagement for models of autoimmunity and In Vitro IO. Of prior experience, Pirouz was with NGM Biopharmaceutical, was a faculty at Miller School of Medicine of University of Miami and a Head Scientist, Cancer Biology, at IMV Inc. Pirouz has authored > 80 peer reviewed papers, has served as a reviewer of DOD, NIH, NCI, is a reviewer for several journals, and acted as a consultant pharma and biotech companies.



Watch Now

Your privacy is important to us.
We'll never share your information.